Ergoteles LLC Oncocyte Corp Transaction History

Ergoteles LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.25 - $15.6 $9,613 - $599,882	38,454 Added 59.8%	102,756 $32,000
Q3 2022 Nov 14, 2022	SELL	$0.76 - $15.98 $127,551 - $2.68 Million	-167,831 Reduced 72.3%	64,302 $47,000
Q2 2022 Aug 12, 2022	BUY	$0.86 - $1.53 $199,634 - $355,163	232,133 New	232,133 $209,000
Q4 2021 Feb 14, 2022	SELL	$2.04 - $3.59 $86,292 - $151,857	-42,300 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.53 - $5.89 $79,778 - $133,114	22,600 Added 114.72%	42,300 $151,000
Q2 2021 Aug 12, 2021	BUY	$3.77 - $6.0 $74,269 - $118,200	19,700 New	19,700 $113,000

411K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $260M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.